Drug Approval | July 26, 2023
NATCO files generic Erdafitinib Tablets in USA
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
There is a pressing need for continuous improvement and innovation in food safety systems to keep pace with emerging food trends and habits
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
To equip them with the latest knowledge and skills to handle patients coming to them in a better way
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Subscribe To Our Newsletter & Stay Updated
